Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 10;15(12):e50297.
doi: 10.7759/cureus.50297. eCollection 2023 Dec.

Correlation Between Oncostatin M and Acute Ischemic Stroke: A Case-Control Study

Michael Christian  1 , Bo Long  1 , Zhanglin Tian  1 , Yuhan Dong  1 , Junmeng Huang  1 , Youdong Wei  1
Affiliations

Correlation Between Oncostatin M and Acute Ischemic Stroke: A Case-Control Study

Michael Christian et al. Cureus. .

Abstract

Background: The expression of oncostatin M (OSM) has been studied in various diseases related to inflammatory response, but its implementation in acute ischemic stroke (AIS) remains to be explored. Objective: The objective of this study is to assess the correlation between serum OSM expression and various aspects of AIS in a clinical setting.

Materials and method: A single-centered case-control study was performed in the First Affiliate Hospital of Chongqing Medical University from October 2020 to March 2021. A total of 134 patients were enrolled in the AIS group and 34 healthy individuals were enrolled in the control group. Physical examinations were performed and venous blood samples were collected. Enzyme-linked immunosorbent assay (ELISA) was used to measure serum OSM. Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification, National Institutes of Health Stroke Scale (NIHSS) score, magnetic resonance imaging (MRI) scan, and modified Rankin scale (mRS) were used to assess the classification, etiology, severity, and prognosis of the AIS group. Assessments were done to analyze serum OSM expression based on sensitivity, etiology, severity, prognosis, and several risk factors of AIS. Regression models, correlation, and sensitivity tests were performed to explore the correlation of OSM expression with various aspects of AIS.

Results: There was a statistically significant elevation of serum OSM expression in the AIS group (P<0.001). All AIS subgroups showed elevation in OSM level and statistically significant results were reflected in three subgroups. The area under the curve to differentiate AIS patients and control by serum OSM level was 0.747 (P<0.001), with the optimal cut-off value showing sensitivity at 58.82% and specificity at 75.37%. The elevation of serum OSM expression was proportional with severity, not proportional to the volume of infarct, and less elevated in the favorable outcome group. Serum OSM correlation with several risk factors of AIS was statistically significant in age, low-density lipoprotein, non-high-density lipoprotein, prothrombin time, and systolic blood pressure.

Conclusion: Serum OSM was expressed differently in correlation with various aspects of AIS. Our findings supported the initial hypothesis that OSM is correlated with various aspects of AIS in humans.

Keywords: acute ischemic stroke; biomarker; correlation; expression; oncostatin m; serum.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Comparison of serum OSM level between the AIS group and the control
AIS: acute ischemic stroke; OSM: oncostatin M
Figure 2
Figure 2. The ROC curve of serum OSM level differentiates between the AIS group and the control group
AIS: acute ischemic stroke; OSM: oncostatin M; ROC: receiver operating characteristics
Figure 3
Figure 3. Correlation between serum OSM expression and various indexes in the AIS group
non-HDL: non-high-density lipoprotein; LDL: low-density lipoprotein; AIS: acute ischemic stroke; OSM: oncostatin M A: cumulative smoking volume, B: age, C: systolic blood pressure, D: non-HDL, E: LDL, and F: prothrombin time
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20:795–820. - PMC - PubMed
    1. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Zhou M, Wang H, Zeng X, et al. Lancet. 2019;394:1145–1158. - PMC - PubMed
    1. The global burden of neurological disorders: translating evidence into policy. Feigin VL, Vos T, Nichols E, et al. Lancet Neurol. 2020;19:255–265. - PMC - PubMed
    1. Global burden, risk factor analysis, and prediction study of ischemic stroke, 1990-2030. Fan J, Li X, Yu X, et al. Neurology. 2023;101:0–50. - PMC - PubMed
    1. China stroke surveillance report 2021. Tu WJ, Wang LD. Mil Med Res. 2023;10:33. - PMC - PubMed

LinkOut - more resources